Joanne Lynn Intile
Works (17)
Updated: April 4th, 2024 10:16
2023 article
Novel genomic prognostic biomarkers for dogs with cancer
Chon, E., Sakthikumar, S., Tang, M., Hamilton, M. J., Vaughan, A., Smith, A., … Wang, G. (2023, October 6). JOURNAL OF VETERINARY INTERNAL MEDICINE, Vol. 10.
author keywords: dog; genes; mutations; outcomes; precision medicine; progression-free survival; real-world; targeted therapy
TL;DR:
Clinical evidence of the potential for genomics and precision medicine in dogs with cancer is provided and the benefit of targeted treatment across multiple cancer types is demonstrated.
(via Semantic Scholar)
onlinelibrary.wiley.com (publisher PDF)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Sources: Web Of Science, ORCID
Added: October 23, 2023
2022 journal article
Discharge summaries provided to owners of pets newly diagnosed with cancer exceed recommended readability levels
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 260(6), 657–661.
MeSH headings : Animals; Comprehension; Internet; Neoplasms / diagnosis; Neoplasms / veterinary; North Carolina; Patient Discharge; United States
TL;DR:
Owner-directed written information regarding a diagnosis of cancer at a single teaching hospital exceeded readability levels recommended by the American Medical Association and NIH and was above the average reading level of most US adults.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
4. Quality Education
(OpenAlex)
Sources: Web Of Science, ORCID
Added: April 18, 2022
2021 article
Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group
Berlato, D., Bulman-Fleming, J., Clifford, C. A., Garrett, L., Intile, J., Jones, P., … Rasotto, R. (2021, April 23). VETERINARY PATHOLOGY, Vol. 4.
author keywords: cancer; pathology; oncology; dogs; mast cell tumor; grading
MeSH headings : Animals; Consensus; Dog Diseases / diagnosis; Dogs; Humans; Mast Cells; Neoplasms / veterinary; Pathologists
TL;DR:
The authors provide a critical review of the current literature for grading of canine cutaneous mast cell tumors, suggest guidelines for reporting, and provide recommendations for its clinical interpretation.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Sources: Web Of Science, ORCID
Added: June 10, 2021
2021 journal article
Veterinary Clinical Ethics and Patient Care Dilemmas
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 51(5), 1079–1097.
author keywords: Ethics/veterinary ethics; Communication; Ethical dilemmas; Patient care
MeSH headings : Animals; Ethics, Clinical; Patient Care / veterinary
TL;DR:
The 4Es model and core communication skills are proposed to be used to address ethical dilemmas in veterinary practice and provide veterinary professionals with an approach to frame and address their own ethical decisions.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Sources: Web Of Science, ORCID
Added: August 16, 2021
2019 chapter
Anal Sac
In E. Cote (Ed.), Clinical Veterinary Advisor: Dogs and Cats (4th ed.). Elsevier.
Ed(s): E. Cote
Source: NC State University Libraries
Added: October 10, 2020
2019 journal article
Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma
JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 55(2), 101–109.
MeSH headings : Animals; Antineoplastic Agents / administration & dosage; Antineoplastic Agents / adverse effects; Antineoplastic Agents / therapeutic use; Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Dacarbazine / administration & dosage; Dacarbazine / adverse effects; Dacarbazine / therapeutic use; Dog Diseases / drug therapy; Dogs; Dose-Response Relationship, Drug; Female; Lymphoma / drug therapy; Lymphoma / veterinary; Male; Mitoxantrone / administration & dosage; Mitoxantrone / adverse effects; Mitoxantrone / therapeutic use; Neutropenia / chemically induced; Neutropenia / veterinary; Retrospective Studies
TL;DR:
The combination of mitoxantrone and DTIC is a safe treatment option for resistant lymphoma in dogs.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Sources: Web Of Science, ORCID
Added: March 4, 2019
2019 chapter
Lymphoma, Rescue Therapy
In E. Cote (Ed.), Clinical Veterinary Advisor: Dogs and Cats (4th ed.). Elsevier.
Ed(s): E. Cote
Source: NC State University Libraries
Added: October 10, 2020
2019 chapter
Perianal
In E. Cote (Ed.), Clinical Veterinary Advisor: Dogs and Cats (4th ed.).
Ed(s): E. Cote
Source: NC State University Libraries
Added: October 10, 2020
2019 review
Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology-Pathology Working Group
[Review of ]. VETERINARY AND COMPARATIVE ONCOLOGY, 17(4), 451–455.
author keywords: cancer; dog; immunohistochemistry; kinase; mutation
MeSH headings : Animals; Dog Diseases / metabolism; Dogs; Gene Expression Regulation, Neoplastic / physiology; Mastocytoma / metabolism; Mastocytoma / veterinary; Mutation; Proto-Oncogene Proteins c-kit / genetics; Proto-Oncogene Proteins c-kit / metabolism; Skin Neoplasms / metabolism; Skin Neoplasms / veterinary
TL;DR:
The intent of this publication is to help educate practitioners and pathologists on the value of diagnostics related to the KIT receptor tyrosine kinase for canine cutaneous mast cell tumours and to provide a guide for the use of these tests in veterinary medicine.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Sources: Web Of Science, ORCID
Added: August 12, 2019
2018 journal article
Dogs with acute myeloid leukemia or lymphoid neoplasms (large cell lymphoma or acute lymphoblastic leukemia) may have indistinguishable mediastinal masses on radiographs
VETERINARY RADIOLOGY & ULTRASOUND, 59(5), 507–515.
author keywords: hematopoietic neoplasia; immunophenotyping; myeloid sarcoma; thorax
MeSH headings : Animals; Cross-Sectional Studies; Dog Diseases / diagnostic imaging; Dog Diseases / etiology; Dogs; Female; Leukemia, Myeloid, Acute / diagnostic imaging; Leukemia, Myeloid, Acute / etiology; Leukemia, Myeloid, Acute / veterinary; Lymphoma, Non-Hodgkin / diagnostic imaging; Lymphoma, Non-Hodgkin / etiology; Lymphoma, Non-Hodgkin / veterinary; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnostic imaging; Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology; Precursor Cell Lymphoblastic Leukemia-Lymphoma / veterinary; Radiography; Retrospective Studies
TL;DR:
In conclusion, acute myeloid leukemia should be considered when a mediastinal mass is detected during radiography in dogs with suspected hematopoietic neoplasia-but the presence or size of a mediastsinal mass does not differentiate between myeloids and lymphoid neoplasms.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Sources: Web Of Science, ORCID
Added: October 16, 2018
2014 journal article
Tolerability of Lomustine in Combination with Cyclophosphamide in Dogs with Lymphoma
Journal of the American Animal Hospital Association, 50(3), 167–173.
MeSH headings : Administration, Oral; Animals; Antineoplastic Agents, Alkylating / administration & dosage; Antineoplastic Agents, Alkylating / adverse effects; Antineoplastic Agents, Alkylating / therapeutic use; Cyclophosphamide / administration & dosage; Cyclophosphamide / adverse effects; Cyclophosphamide / therapeutic use; Dog Diseases / drug therapy; Dog Diseases / pathology; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule / veterinary; Lomustine / administration & dosage; Lomustine / adverse effects; Lomustine / therapeutic use; Lymphoma / drug therapy; Lymphoma / veterinary; Retrospective Studies; Treatment Outcome
TL;DR:
On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/ m( 2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(OpenAlex)
Sources: Crossref, ORCID
Added: November 16, 2019
2010 journal article
A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours
Veterinary and Comparative Oncology, 8(2), 138–152.
author keywords: chemotherapy; oncology; small animal
MeSH headings : Animals; Antineoplastic Agents, Alkylating / administration & dosage; Antineoplastic Agents, Alkylating / adverse effects; Antineoplastic Agents, Hormonal / administration & dosage; Antineoplastic Agents, Hormonal / adverse effects; Antineoplastic Agents, Phytogenic / administration & dosage; Antineoplastic Agents, Phytogenic / adverse effects; Antineoplastic Combined Chemotherapy Protocols / administration & dosage; Antineoplastic Combined Chemotherapy Protocols / adverse effects; Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Dog Diseases / drug therapy; Dog Diseases / pathology; Dogs; Female; Lomustine / administration & dosage; Lomustine / adverse effects; Male; Mastocytosis / drug therapy; Mastocytosis / pathology; Mastocytosis / veterinary; Neoplasm Staging; Neutropenia / chemically induced; Neutropenia / veterinary; Prednisone / administration & dosage; Prednisone / adverse effects; Survival Analysis; Treatment Outcome; Vinblastine / administration & dosage; Vinblastine / adverse effects
TL;DR:
Safety and efficacy of a protocol of alternating 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and vinblastine and prednisone in dogs with mast cell tumours were evaluated and response rate was 65%; five achieved a complete response and six achieved a partial response.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(OpenAlex)
Sources: Crossref, ORCID
Added: November 16, 2019
2010 journal article
Comparison between l-CHOP and an l-CHOP protocol with interposed treatments of CCNU and MOPP (l-CHOP-CCNU-MOPP) for lymphoma in dogs
Veterinary and Comparative Oncology, 8(4), 243–253.
author keywords: chemotherapy; oncology; small animal
MeSH headings : Animals; Antineoplastic Combined Chemotherapy Protocols / administration & dosage; Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Asparagine / administration & dosage; Asparagine / therapeutic use; Cyclophosphamide / administration & dosage; Cyclophosphamide / therapeutic use; Dog Diseases / drug therapy; Dogs; Doxorubicin / administration & dosage; Doxorubicin / therapeutic use; Female; Lomustine / administration & dosage; Lomustine / therapeutic use; Lymphoma / drug therapy; Lymphoma / veterinary; Male; Mechlorethamine / administration & dosage; Mechlorethamine / therapeutic use; Prednisone / administration & dosage; Prednisone / therapeutic use; Procarbazine / administration & dosage; Procarbazine / therapeutic use; Retrospective Studies; Risk Factors; Vincristine / administration & dosage; Vincristine / therapeutic use
TL;DR:
The L-CHOP-CCNU-MOPP protocol showed an improved duration of first CR as compared with an L- CHOP protocol, but the relevance of this finding might be subject to clinical judgement.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(OpenAlex)
Sources: Crossref, ORCID
Added: November 16, 2019
2010 journal article
Phase II, Open-Label Trial of Single-Agent CCNU in Dogs with Previously Untreated Histiocytic Sarcoma
Journal of Veterinary Internal Medicine, 24(6), 1528–1531.
author keywords: Canine; Chemotherapy; Clinical trial; Oncology treatment
MeSH headings : Animals; Antineoplastic Agents / administration & dosage; Antineoplastic Agents / therapeutic use; Dog Diseases / drug therapy; Dogs; Female; Histiocytic Sarcoma / drug therapy; Histiocytic Sarcoma / veterinary; Lomustine / administration & dosage; Lomustine / therapeutic use; Male
TL;DR:
CCNU, when used as a single agent, has activity against HS in dogs, and Evaluation of CCNU postoperatively for dogs with resectable localized HS and as part of combination therapy for tumors that are nonresectable or disseminated should be considered.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(OpenAlex)
Sources: Crossref, ORCID
Added: November 16, 2019
2009 journal article
Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs
Veterinary and Comparative Oncology, 7(1), 69–77.
author keywords: CCNU; corticosteroids; haematologic toxicity; lomustine; neutropenia
MeSH headings : Animals; Antineoplastic Agents, Alkylating / administration & dosage; Bone Marrow / drug effects; Dexamethasone / pharmacology; Dog Diseases / blood; Dog Diseases / drug therapy; Dogs; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Glucocorticoids / pharmacology; Lomustine / administration & dosage; Neutropenia / blood; Neutropenia / drug therapy; Neutropenia / veterinary; New York; Schools, Veterinary; Treatment Outcome
TL;DR:
Pretreatment with dexamethasone did not reduce the incidence of grade 4 neutropenia in dogs receiving CCNU, and peak plasma concentrations after a single oral 0.1-mg kg(-1) dose were <80 ng mL(-1), the minimum level associated with chemoprotective effects of dexamETHasone in people.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(OpenAlex)
Sources: Crossref, ORCID
Added: November 16, 2019
2008 journal article
Efficacy of Vinblastine for Treatment of Canine Mast Cell Tumors
Journal of Veterinary Internal Medicine, 22(6), 1390–1396.
author keywords: Chemotherapy; Dog; Oncology
MeSH headings : Animals; Antineoplastic Agents / administration & dosage; Antineoplastic Agents / therapeutic use; Dog Diseases / drug therapy; Dogs; Dose-Response Relationship, Drug; Female; Male; Mastocytosis / drug therapy; Vinblastine / administration & dosage; Vinblastine / therapeutic use
TL;DR:
Findings suggest VBL at a dosage of 3.5 mg/m2 should be considered for use in future phase II/III trials, although the response rate is lower than those reported for VBL-containing combination protocols.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(OpenAlex)
Sources: Crossref, ORCID
Added: November 16, 2019
2001 journal article
A mechanism for combinatorial regulation of electrical activity: Potassium channel subunits capable of functioning as Src homology 3-dependent adaptors
Proceedings of the National Academy of Sciences, 98(2), 705–710.
UN Sustainable Development Goal Categories
6. Clean Water and Sanitation
(OpenAlex)
Sources: Crossref, ORCID
Added: November 16, 2019
Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.
Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
